NEW YORK (GenomeWeb) – A newly launched five-oncogene, next-generation sequencing-based panel has allowed Intermountain Healthcare to analyze cancer patients with limited tissue samples hoping to receive personalized treatment, while also helping the healthcare system to significantly lower its test rejection rate.
Mutations in the five genes gauged by Intermountain’s CG100 Onco Focus Panel ― KRAS, BRAF, NRAS, EGFR, and KIT ― are more likely to show up in lung, melanoma, and colon cancer patients and can be targeted by marketed drugs. These aspects, and the fact that the smaller panel is cheaper to perform than a more comprehensive test that Intermountain offers, makes it more likely to be reimbursed by insurers, providers are hoping.
Four years ago, Intermountain began offering Stage IV metastatic cancer patients the chance to receive genomic profiling on a 100-gene panel. The Salt Lake City-headquartered healthcare system recently expanded the panel to include 162 genes associated with cancer pathways. The ICG100 Comprehensive Cancer Panel gauges around 4,000 SNPs, large and small indels, and copy number variations, but requires about 150 nanograms of DNA, according to David Loughmiller, core lab manager at Intermountain Precision Genomics, which provides genomic sequencing services for Intermountain Healthcare.
By comparison, the smaller